January 16, 2016
Dr. Charles R. Hamel, MD gave an overview of the therapy known as Low Dose Immunotherapy (LDI), Small intestinal bacterial overgrowth (SIBO), and connections to autoimmune disease. His talk was followed by a lively question and answer session.
Dr. Hamel briefly outlined the developmental progression and investigating doctors involved. The therapy was originally termed, “enzyme potentiated desensitization.”
The LDI treatment concept, developed by Ty
Vincent, MD of Fairbanks, Alaska, is an outgrowth of the Low Dose Antigen (LDA) therapy. LDA targets sensitivities to foods, chemicals and airborne substances. Some patients consult with Dr. Vince
nt via Skype. LDA and LDI can be given simultaneously. An example protocol sheet was provided to the attendees.
Symptomatic patients tend to have abnormal helper to suppressor cell ratios. One goal of treatment is to help the body produce the correct amount of suppressor cells which work to decrease inflammation. Full development of suppressor cells is expected in 21 days from the LDI dose with the subsequent dose following in 7-8 weeks. Cortisone can be used to ameliorate any distressing post-treatment symptoms.